title: Synergistic acceleration of thyroid hormone degradation by phenobarbital and the PPAR alpha agonist WY14643 in rat hepatocytes.
abstract: Energy balance is maintained by controlling both energy intake and energy expenditure. Thyroid hormones play a crucial role in regulating energy expenditure. Their levels are adjusted by a tight feedback-controlled regulation of thyroid hormone production/incretion and by their hepatic metabolism. Thyroid hormone degradation has previously been shown to be enhanced by treatment with phenobarbital or other antiepileptic drugs due to a CAR-dependent induction of phase II enzymes of xenobiotic metabolism. We have recently shown, that PPAR alpha agonists synergize with phenobarbital to induce another prototypical CAR target gene, CYP2B1. Therefore, it was tested whether a PPAR alpha agonist could enhance the phenobarbital-dependent acceleration of thyroid hormone elimination. In primary cultures of rat hepatocytes the apparent half-life of T3 was reduced after induction with a combination of phenobarbital and the PPAR alpha agonist WY14643 to a larger extent than after induction with either compound alone. The synergistic reduction of the half-life could be attributed to a synergistic induction of CAR and the CAR target genes that code for enzymes and transporters involved in the hepatic elimination of T3, such as OATP1A1, OATP1A3, UGT1A3 and UGT1A10. The PPAR alpha-dependent CAR induction and the subsequent induction of T3-eliminating enzymes might be of physiological significance for the fasting-induced reduction in energy expenditure by fatty acids as natural PPAR alpha ligands. The synergism of the PPAR alpha agonist WY14643 and phenobarbital in inducing thyroid hormone breakdown might serve as a paradigm for the synergistic disruption of endocrine control by other combinations of xenobiotics.
authors.affiliation: University of Potsdam, Institute of Nutrition Science, Biochemistry of Nutrition, Arthur-Scheunert-Allee 114-116, D14558 Nuthetal, Germany.
authors.forename: N
authors.initials: N
authors.lastname: Wieneke
authors.forename: F
authors.initials: F
authors.lastname: Neuschäfer-Rube
authors.forename: L M
authors.initials: LM
authors.lastname: Bode
authors.forename: M
authors.initials: M
authors.lastname: Kuna
authors.forename: J
authors.initials: J
authors.lastname: Andres
authors.forename: L C
authors.initials: LC
authors.lastname: Carnevali
authors.forename: K I
authors.initials: KI
authors.lastname: Hirsch-Ernst
authors.forename: G P
authors.initials: GP
authors.lastname: Püschel
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D004357:Drug Synergism; D022781:Hepatocytes / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism*; D008297:Male; D047493:PPAR alpha / Q000819:agonists* / Q000378:metabolism; D010634:Phenobarbital / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013974:Thyroxine / Q000378:metabolism*; D014284:Triiodothyronine / Q000378:metabolism*
chemical_list: D047493:PPAR alpha; D011743:Pyrimidines; D014284:Triiodothyronine; C006253:pirinixic acid; D013974:Thyroxine; D010634:Phenobarbital